Zacks Research Weighs in on Cencora’s Q2 Earnings (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Cencora in a research report issued on Wednesday, February 26th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings of $4.05 per share for the quarter, down from their previous forecast of $4.11. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora’s Q4 2025 earnings at $3.76 EPS, FY2025 earnings at $15.28 EPS and Q3 2026 earnings at $4.30 EPS.

COR has been the subject of a number of other research reports. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Mizuho began coverage on Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. UBS Group upped their price target on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Trading Up 0.7 %

NYSE COR opened at $255.22 on Monday. Cencora has a 1-year low of $214.77 and a 1-year high of $262.26. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock has a 50-day moving average of $241.71 and a 200-day moving average of $237.85. The firm has a market cap of $49.49 billion, a PE ratio of 36.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is 31.29%.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in COR. Norges Bank purchased a new position in shares of Cencora during the 4th quarter worth approximately $478,309,000. Pacer Advisors Inc. grew its stake in shares of Cencora by 6,855.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock worth $464,874,000 after buying an additional 2,035,679 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Cencora by 62.3% in the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock worth $1,166,944,000 after buying an additional 1,994,256 shares during the last quarter. Castlekeep Investment Advisors LLC purchased a new stake in shares of Cencora in the 4th quarter worth approximately $399,508,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Cencora in the 4th quarter worth approximately $322,460,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.